Emerging Approaches and Patient‐centered Care for Narcolepsy

Access Activity

Overview / Abstract:

Target Audience

The primary target audiences for the HCP activity are neurologists, sleep specialists, and specialty NPs and PAs. Secondary audiences include primary care physicians, internists, advanced practitioners, pharmacists, and nurses

Statement of Need/Program Overview

Narcolepsy is a chronic neurologic disorder characterized by excessive daytime sleepiness (EDS), sleep paralysis, hypnagogic and hypnopompic hallucinations, disrupted nocturnal sleep, dysregulated rapid eye movement (REM) sleep, and cataplexy in most patients. Despite these obvious symptoms, narcolepsy is often under‐recognized, with diagnostic delays of up to 15 years, or misdiagnosed, depriving patients of appropriate treatment and care. However, if diagnosed accurately, emerging agents for narcolepsy could provide a new, patient‐centered management option.

Join a panel of expert clinicians and patient representatives for an in-depth discussion of the shifting standards of care for narcolepsy with or without cataplexy. Panelists will discuss strategies to address barriers to the recognition of the disorder and detail assessment tools and methods to ensure an accurate and timely diagnosis. In addition, the education will explore highly anticipated upcoming and more patient centered agents, indications, and classes of agents that are expected to further refine the narcolepsy treatment armamentarium.

Do you have patients who could benefit from related education on the recognition and care of narcolepsy? Direct your patients to MedLive.com to access the related patient-education activity, “More than Sleepiness: How Recognizing and Treating Narcolepsy Will Impact the Entire Family.”

Educational Objectives

Upon completion of this activity, the participant should be better able to:

Describe signs and symptoms that support a suspicion of narcolepsy with/without cataplexy
Formulate a differential diagnosis for narcolepsy with/without cataplexy
Describe the adverse effects of EDS and interrupted sleep on patient QoL and overall health
Assess the safety, efficacy, and tolerability profiles of available and investigational therapies for the treatment of narcolepsy with/without cataplexy

Expiration

Dec 13, 2022

Discipline(s)

Physician CME

Format

Online

Credits / Hours

1.0 AMA PRA Category 1 Credit(s)™

Accreditation

ACCME

Presenters / Authors / Faculty

Faculty

Emmanuel Mignot, MD, PhD
Craig Reynolds Professor of Sleep Medicine
Stanford University

Michael Thorpy, MD
Professor of Neurology
Albert Einstein College of Medicine

Sponsors / Supporters / Grant Providers

Avadel Pharmaceuticals.

Keywords / Search Terms

Relias LLC Relias LLC., FreeCME., Narcolepsy Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map